Abstract
Benefit-Risk Assessment Based on Number Needed to Treat and Number Needed to Harm: Atogepant vs Calcitonin Gene–Related Peptide Monoclonal Antibodies (P5-12.007)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have